ALS and FTLD: two faces of TDP-43 proteinopathy

Abstract

Major discoveries have been made in the recent past in the genetics, biochemistry and neuropathology of frontotemporal lobar degeneration (FTLD). TAR DNA-binding protein 43 (TDP-43), encoded by the TARDBP gene, has been identified as the major pathological protein of FTLD with ubiquitin-immunoreactive (ub-ir) inclusions (FTLD-U) with or without amyotrophic lateral sclerosis (ALS) and sporadic ALS. Recently, mutations in the TARDBP gene in familial and sporadic ALS have been reported which demonstrate that abnormal TDP-43 alone is sufficient to cause neurodegeneration. Several familial cases of FTLD-U, however, are now known to have mutations in the progranulin (GRN) gene, but granulin is not a component of the TDP-43- and ub-ir inclusions. Further, TDP-43 is found to be a component of the inclusions of an increasing number of neurodegenerative diseases. Other FTLD-U entities with TDP-43 proteinopathy include: FTLD-U with valosin-containing protein (VCP) gene mutation and FTLD with ALS linked to chromosome 9p. In contrast, chromosome 3-linked dementia, FTLD-U with chromatin modifying protein 2B (CHMP2B) mutation, has ub-ir, TDP-43-negative inclusions. In summary, recent discoveries have generated new insights into the pathogenesis of a spectrum of disorders called TDP-43 proteinopathies including: FTLD-U, FTLD-U with ALS, ALS, and a broadening spectrum of other disorders. It is anticipated that these discoveries and a revised nosology of FTLD will contribute toward an accurate diagnosis, and facilitate the development of new diagnostic tests and therapeutics.

Full text

ALS and FTLD: two faces of TDP-43 proteinopathy
R. M. Liscica,b, L. T. Grinbergb,c,d,e, J. Zidarf, M. A. Gitchob,g, and N. J. Cairnsb,e,g
a Institute for Medical Research and Occupational Health, Zagreb, Croatia
b Alzheimer’s Disease Research Center, Washington University School of Medicine, St Louis,
MO, USA
c Department of Pathology, University of São Paulo Medical School, São Paulo, Brazil
d Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
e Pathology & Immunology, Washington University School of Medicine, St Louis, MO, USA
f Institute of Clinical Neurophysiology, University Medical Centre, Ljubljana, Slovenia
g Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Abstract
Major discoveries have been made in the recent past in the genetics, biochemistry and
neuropathology of frontotemporal lobar degeneration (FTLD). TAR DNA-binding protein 43
(TDP-43), encoded by the TARDBP gene, has been identified as the major pathological protein of
FTLD with ubiquitin-immunoreactive (ub-ir) inclusions (FTLD-U) with or without amyotrophic
lateral sclerosis (ALS) and sporadic ALS. Recently, mutations in the TARDBP gene in familial
and sporadic ALS have been reported which demonstrate that abnormal TDP-43 alone is sufficient
to cause neurodegeneration. Several familial cases of FTLD-U, however, are now known to have
mutations in the progranulin (GRN) gene, but granulin is not a component of the TDP-43- and ub-
ir inclusions. Further, TDP-43 is found to be a component of the inclusions of an increasing
number of neurodegenerative diseases. Other FTLD-U entities with TDP-43 proteinopathy
include: FTLD-U with valosin-containing protein (VCP) gene mutation and FTLD with ALS
linked to chromosome 9p. In contrast, chromosome 3-linked dementia, FTLD-U with chromatin
modifying protein 2B (CHMP2B) mutation, has ub-ir, TDP-43-negative inclusions. In summary,
recent discoveries have generated new insights into the pathogenesis of a spectrum of disorders
called TDP-43 proteinopathies including: FTLD-U, FTLD-U with ALS, ALS, and a broadening
spectrum of other disorders. It is anticipated that these discoveries and a revised nosology of
FTLD will contribute toward an accurate diagnosis, and facilitate the development of new
diagnostic tests and therapeutics.
Keywords
amyotrophic lateral sclerosis; frontotemporal dementia; frontotemporal lobar degeneration;
granulin; motor neuron disease; TARDBP; TDP-43; ubiquitin; valosin-containing protein
Correspondence: Nigel J. Cairns, PhD, FRCPath, Department of Pathology and Immunology, Washington University School of
Medicine, Campus Box 8118, 660 South Euclid Avenue, St Louis, MO 63110, USA (tel.: +1 314 362 7420; fax: +1 314 362 4096;
cairns@wustl.edu).
Disclosure
The authors report no conflicts of interest.
NIH Public Access
Author Manuscript
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
Published in final edited form as:
Eur J Neurol
. 2008 August ; 15(8): 772–780. doi:10.1111/j.1468-1331.2008.02195.x.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Introduction
Frontotemporal lobar degeneration (FTLD) is used here as an umbrella term to include both
a clinical syndrome and one of the neuropathological entities [1–3]. FTLD is a focal, non-
Alzheimer form of dementia, clinically characterized as either behavioral or aphasic variants
[1,2,4]. Most commonly, the behavioral or frontal variant is characterized by behavioral
dysfunction and change in personal and social conduct. The aphasic variant includes a non-
fluent form called progressive non-fluent aphasia, and a fluent form called semantic
dementia. Typically, the patient with FTLD does not have an amnestic syndrome, at least in
the early stage of the disease, which distinguishes FTLD clinically from Alzheimer’s disease
(AD) [5], but there are exceptions [6]. Focal dementias account for up to 20% of presenile
dementia cases [7], and FTLD is the second most frequent form of dementia in people under
the age of 65 years after AD [8]. FTLD may occur alone or in combination with
amyotrophic lateral sclerosis (ALS), parkinsonism, or corticobasal syndrome during the
course of the disease.
ALS is the most common adult-onset progressive and, ultimately fatal, motor neuron disease
(MND). Like FTLD, ALS encompasses a range of clinicopathological entities [9]. ALS is
used here to describe signs of upper and lower motor neuron degeneration with a
progressive spread of signs within a region or to other regions as defined by the El Escorial
World Federation of Neurology Criteria [10]. The overlap between dementia and ALS is
demonstrated by the presence of cognitive and behavioral dysfunction in up to 50% of ALS
patients [10–16], indicating a spectrum of clinical phenotypes that relate to common
neuropathological lesions [17–19]. Further evidence for a clinical overlap between FTLD
and ALS is the occurrence of progressive aphasia [20,21] and the presence of
frontotemporal atrophy [22] in patients with ALS. Incidence rates of FTLD with ALS vary
often as a consequence of referral bias and differing diagnostic criteria. Several studies have
shown that ALS patients with frontotemporal impairment have significantly shorter survival
compared with FTLD patients [23,24]. However, the clinical diagnosis of FTLD may only
be considered after other potential causes of dementia (e.g. small and/or large vessel
disease), systemic conditions (e.g. hypothyroidism, B-vitamin deficiency), tumors, and
substance abuse have been excluded. This review will highlight a number of important
advances in our understanding of the molecular genetics, biochemistry, and neuropathology
of FTLD that have occurred within the recent past.
Genetic studies
FTLD is a genetically complex disorder, with multiple genetic factors contributing to the
disease. A positive family history with an autosomal dominant pattern of inheritance and
high penetrance is usually found in one quarter to one half of patients [25–30]. Recently,
several genes and a locus on chromosome 9p have been linked to familial FTLD with
ubiquitin-immunoreactive, tau-negative inclusions (FTLD-U): genetic defects include
mutations in the chromatin modifying protein 2B (CHMP2B gene), the cause of
chromosome 3-linked FTLD [31], and mutations in the valosin-containing protein (VCP)
gene, a cause of chromosome 9-linked FTLD [32,33]. Locus heterogeneity for FTLD and
ALS is indicated by the presence of other genetic loci at 9p [34,35]. Recently, the major
genetic cause of familial FTLD-U linked to chromosome 17 was identified as mutations in
the progranulin (GRN) [36,37] gene. This discovery was soon replicated by the
identification of other GRN mutations in the HDDD2 [38], PPA1 and PPA3 [39], and
HDDD1 [40] families. Although null mutations, mainly nonsense and frameshift mutations
resulting in premature stop codons, in GRN were the first to be identified and the causal
mechanism underlying FTLD-U, some of the families described have missense mutations
which are predicted to alter trafficking, protein folding, or processing leading to a GRN
Liscic et al. Page 2
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

protein haploinsufficiency [36,37]. Thus, a spectrum of mutations in GRN leads to loss of
functional protein, the primary etiology of FTLD with GRN mutation.
This genetic heterogeneity is also reflected in clinical variability. FTLD with GRN mutation
has been described in families with corticobasal syndrome [41–43] and in familial and
sporadic patients from large FTLD cohorts [44–48]. In 37 patients with a single gene defect,
Arg493X, in 30 families with FTLD, there was a variable age at onset (range 44–69 years)
and clinical diagnoses included: frontotemporal dementia, primary progressive aphasia,
corticobasal syndrome, and Alzheimer’s disease [47]. In contrast, there is phenotypical
homogeneity in the PPA1 and PPA3 families, at least in the initial stage of disease [39].
Also, FTLD with GRN A9D, a missense mutation located in the signal peptide, has been
described in a family with corticobasal syndrome [43] as well as in another family
(HDDD2) with prominent behavioral and language dysfunction [38]. Thus, FTLD with GRN
mutation is both clinically, neuropathologically, and genetically heterogeneous [36–50].
Most of the mutations reported to date, but not all, lead to premature termination of the
coding sequence and nonsense mediated decay (NMD) resulting in functional loss of one
allele. The overall effect of these changes is likely to be a significant reduction in the growth
modulator activity of GRN. The various GRN mutations predict at least two disease
mechanisms – the partial loss of functional GRN (haploinsufficiency) [36,37] or functional
loss caused by mis-trafficking of mutant protein [38,49]. Further studies are required to
expand the spectrum of FTLD phenotypes with the several GRN mutations that have now
been reported [36–50]. (For the current list of pathogenic mutations in FTLD refer to:
http://www.molgen.ua.ac.be/FTDMutations/).
FTLD-U accounts for 5–15% of all dementia disorders [51]. Mutations in the microtubule-
associated protein tau (MAPT) gene on chromosome 17q21 which, coincidentally, is in
close proximity to the GRN gene, are known to be responsible for 10–20% of familial FTLD
[52]. The progranulin gene (GRN) is mutated in 5–10% of patients with FTLD and in about
20% of patients with familial FTLD [53], similar to that of FTLD with MAPT mutation [52].
The recent discovery of pathogenic missense mutations in a highly conserved glycine-rich,
heterogeneous ribonucleoprotein interacting domain of the TARDBP gene (Fig. 1) in
autosomal dominant ALS families and sporadic cases confirms the importance of TDP-43 in
the pathogenesis of ALS and demonstrates that defects in TARDBP are sufficient to cause
TDP-43 proteinopathy [54–57]. In none of these families, or in any of the sporadic cases,
was there evidence of FTLD. As additional families are identified, more heterogeneous
clinical phenotypes may emerge. As the glycine-rich domain (Fig. 1) is a ‘hot spot’ for the
mutations reported so far, dysregulation of mRNA splicing may be the functional
consequence of these gene defects. A great deal of work has yet to be done to elucidate the
normal function of TDP-43 and the cellular pathways disrupted by abnormal protein caused
by mutations in TARDBP. As some familial FTLD-U cases do not have GRN, VCP,
CHMP2B, or TARDBP mutations, it is likely that additional causal genes and genetic risk
factors for FTLD-U exist.
Neuropathology
FTLD comprises a neuropathologically heterogeneous group of neurodegenerative diseases,
which share the common feature of preferential degeneration of the frontal and temporal
lobes [1,4]. FTLD pathology can be broadly divided into two main classes, based on
abnormal accumulation of hyperphosphorylated tau protein: those with tau-immunoreactive
(tau-ir) neuronal and/or glial inclusions called tauopathies and those with ubiquitin-
immunoreactive (ub-ir), tau-negative inclusions, called FTLD-U. FTLD-U is the most
common entity within this group [58]. ALS is also accompanied by a wide range of
Liscic et al. Page 3
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

neuropathological features in which both cortical (upper motor neuron), and either brainstem
motor neurons or anterior horn cells (lower motor neuron) are involved with a signature
lesion: abnormal accumulation of insoluble proteins, which are ubiquitinated, in the
cytoplasm of degenerating motor neurons [59]. Ub-ir inclusions are observed more
commonly in sporadic ALS (SALS), but they are also seen in familial ALS (FALS) with Cu/
Zn superoxide dismutase (SOD1) gene mutations [60,61]. Until recently, ubiquitin
immunohistochemistry (IHC) was the only method to detect abnormal protein aggregates in
FTLD-U, FTLD-U with ALS, and SALS. In this spectrum of diseases, the ubiquitinated
inclusions contain neither tau, nor α-synuclein, nor neuronal intermediate filament protein
epitopes.
Recently, TAR DNA-binding protein 43 (TDP-43) [18,19], was identified as the major
component of inclusions of sporadic and familial FTLD-U, with and without ALS, and
SALS (Fig. 2) [60,62]. However, the absence of pathological TDP-43 in familial cases
harboring SOD1 gene mutations implies that motor neuron degeneration may result from a
different mechanism in those cases [60]. It remains to be seen if TDP-43 may be useful in
differentiating SOD1-related ALS from SALS [60].
Neuropathologically, the TDP-43 proteinopathies are characterized by ubiquitin- and
TDP-43-ir neuronal cytoplasmic inclusions (NCIs), neuronal intranuclear inclusions (NIIs),
dystrophic neurites (DNs) and, in cases of MND, glial cytoplasmic inclusions (GCIs)
[18,19,63–67]. The pathological inclusions of these disorders may be distinguished from
other protein folding diseases which are characterized by abnormal aggregates of tau, α-
synuclein, β-amyloid, neuronal intermediate filament proteins, or expanded polyglutamine
repeats. TDP-43 proteinopathy is characterized biochemically by the presence of relatively
insoluble ubiquitinated TDP-43-containing inclusions of which TDP-43 is abnormally
phosphorylated and cleaved to produce C-terminal fragments [18,19,62,64–66]. The
variability in the distribution and morphology of ub-ir or TDP-43-ir inclusions in FTLD-U
has led to the development of a classification of FTLD-U into four pathological subtypes
based on the morphology of the inclusion, its location within the cell, and the density and
distribution in the frontal and/or temporal lobes (Fig. 3) [3,62,67]. These different
pathological subtypes correlate, although imperfectly, with the molecular genetic and
clinical phenotype [68]. Alternative schemes have been proposed and additional studies are
required to determine their validity [62,68]. The discovery of TDP-43 as a novel misfolded
protein links a spectrum of diseases including FTLD, ALS, Alzheimer’s disease [69], Lewy
body disease [70] and Guam parkinsonism-dementia complex [71] by a common molecular
pathology called TDP-43 proteinopathy. The identification of this protein as a major or
minor component of the pathological inclusions of a spectrum of neurodegenerative disease
provides new clues into the pathogenesis of protein aggregation, and it presents new targets
for therapeutic intervention where none exists.
TDP-43 proteinopathy is also a signature feature of other rare familial diseases. Inclusion
body myopathy associated with Paget’s disease of bone and frontotemporal dementia
(IBMPFD) is a rare autosomal dominant disorder caused by a mutation in the VCP gene
[32,33,62]. IBMPFD is a distinct subtype of FTLD-U with numerous DNs and NIIs [33,62].
As with cases of FTLD-U with GRN mutation, the ubiquitinated inclusions are not primarily
composed of the mutated protein VCP, but rather TDP-43 [62]. Recently, a new genetic
locus on chromosome 9p for familial ALS with or without FTLD has been described
[34,35]. Neuropathology of some of these families reveals the characteristic lesions of
FTLD-U: ub-ir and TDP-43-ir NCIs, DNs, and NIIs indicating that another gene locus on
chromosome 9 may precipitate TDP-43 proteinopathy [3].
Liscic et al. Page 4
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

FTLD linked to chromosome 3 is an FTLD-U with mutation in the CHMP2B gene and is an
exception to the FTLD-U entities described above [31]. Early reports of this kindred
described the neuropathology as ‘dementia lacking distinctive histopathology’ (DLDH).
Subsequently, improved IHC methods revealed ub-ir, but TDP-43-negative, granular NCIs
in frontal neo-cortex and hippocampus [62,72]. Thus, rarely, FTLD-U may not be a TDP-43
proteinopathy. In the light of these recent immunohistochemical, biochemical, and genetic
advances, the Consortium for Frontotemporal Lobar Degeneration has developed an
algorithm to facilitate diagnosis and revised neuropathological diagnostic criteria (Table 1)
[3]. These criteria will be of value to the practicing clinician and provide a foundation for
clinical, clinico-pathological, and mechanistic studies and in vivo models of the pathogenesis
of FTLD.
Clinical evaluation
In addition to being the causative gene defect in autosomal dominantly inherited FTLD with
GRN mutation, a mutation in GRN may rarely occur in supposedly sporadic FTLD-U. Both
behavioral and aphasic forms of FTLD can be associated with these gene defects [45–
47,68], although the behavioral variant is the most common clinical phenotype associated
with FTLD with GRN mutation [46,47]. Magnetic resonance imaging and 18-fluoro-
deoxyglucose positron emission tomography helps discriminate AD from FTLD [73–77].
Patients with GRN mutations have predominant frontal, temporal and, to lesser extent,
parietal atrophy and hypometabolism with a right-sided predominance and this probably
relates to the predominance of behavioral symptoms [74]. However, language dysfunction in
patients with FTLD with GRN mutation show a left-sided predominance of atrophy on
imaging [45,78].
Several FTLD with GRN mutation families have been described: hereditary dysphasic
disinhibition dementia families 1 and 2 (HDDD1 and 2) [79,80] and other kindreds with a
similar clinical phenotype [37,75], UBC-17 [50,81], and aphasic families described by
Mesulam et al. [39] and Snowden et al. [82]. Interestingly, the HDDD1 and HDDD2
kindreds are characterized pathologically by FTLD-U and additional AD-type pathology,
which distinguishes them from other reported families with no or little coexisting
neurodegenerative disease [36,37]. Another family with the same GRN A9D mutation has
been reported in an individual with corticobasal syndrome [43] indicating, again, clinical
heterogeneity associated with the same mutation. Unlike most other FTLD-U with GRN
mutation families [47], the HDDD1 mutation carriers also had AD-type early-memory loss
which correlated with coexisting AD pathology [40]. The overlap between FTLD-U and AD
in familial cases is important as 23% of AD cases show FTLD-U type TDP-43 pathology
[67].
Recent discoveries in the molecular genetics, biochemistry, and neuropathology of FTLD
have transformed our understanding of this hitherto enigmatic group of diseases. TDP-43
has been identified as the major pathological protein of a spectrum of diseases which
includes FTLD-U, FTLD-U with ALS, and sporadic ALS, and a minor component of the
inclusions of a widening spectrum of other diseases. The physiological function of TDP-43
in the brain is currently unknown; however, it is normally localized to the nucleus of
neurons and some glial cells [19,64,65]. Although the specific role of TDP-43 in
neurodegeneration remains speculative, some studies indicate that this protein is directly
involved in the pathogenesis of SALS, ALS with dementia and FTLD-U [18,19,60,61]. The
most common FTLD is FTLD-U and accounts for more than one half of all FTLD entities in
most studies [51,52]. Ubiquitin and TDP-43 immunohistochemistry may be used to
distinguish four subtypes of FTLD-U which correlate with genotype and neuropathological
phenotype [62,67], but mutation analysis will be required to determine the genetic cause in
Liscic et al. Page 5
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

familial cases. Additional studies of larger groups of cases are required to determine the
utility of the FTLD-U subtypes that have been described. The identification of different
mutations in the GRN gene in HDDD kindreds [38,40] links these families to other FTLD-U
families in which GRN mutations have been identified [36,37,43,50,68], but the HDDD
kindreds appear to be distinctive both clinically and pathologically. Further studies are
required to describe more accurately the clinical and neuropathological heterogeneity
associated with different gene defects that result in FTLD-U.
The identification of the causative gene defect in a patient with FTLD and/or ALS may
provide some insight into clinical and neuropathological variation that may be present.
Clinical studies of ALS, FTLD and FTLD with ALS have found significant clinical overlap,
indicating a spectrum of phenotypes, suggesting that they represent different manifestations
of the same neurodegenerative disorder [17,83]. The clinical overlap between ALS and
FTLD has also been illustrated in a study of 36 FTLD patients, five of whom met clinical
and electrophysiological criteria for definite ALS and an additional one-third met criteria for
possible ALS [15]. In contrast, in 100 consecutive ALS patients, frontal executive deficits
were present in half of ALS patients, many of whom met research criteria for FTLD [16]. In
patients with bulbar onset ALS, however, the incidence of FTLD has been reported as high
as 48% [14]. The presence of TDP-43 proteinopathy in cases with sporadic ALS, ALS with
FTLD, and FTLD links clinical phenotypes by a common molecular pathology. The absence
of pathological TDP-43, however, in ALS with SOD1 mutation may partially explain why
therapeutic strategies, shown to be effective in SOD1 mouse models, have not been effective
in clinical trials of patients with sporadic ALS [83–85].
Conclusion
FTLD and ALS are clinically, genetically, and neuropathologically heterogeneous. FTLD
can no longer be considered a rare group of disorders as it accounts for 5–10% of dementia
cases in most dementia centers. Although ALS and FTLD phenotypes may be distinguished
in the clinic, it is not usually possible to determine which neuropathological entity is
responsible for the clinical presentation. In familial cases, molecular genetics may identify
the causative gene but, at present, there is no effective treatment. Two distinct FTLD entities
have been linked to chromosome 17: FTLD-U with GRN mutation and FTLD with
microtubule-associated protein tau (MAPT) mutation. TDP-43 is the major pathological
protein of the motor neuron inclusions found in FTLD-U, FTLD-U with ALS, SALS, FALS,
but not FALS with SOD1 mutation, and G-PDC, and is a minor component of the inclusions
of other disorders including the neurofibrillary tangles of AD, Lewy bodies of Parkinson’s
disease and dementia with Lewy bodies, and the ubiquitinated inclusions of some cases of
hippocampal sclerosis. TDP-43 proteinopathies are distinct from most other
neurodegenerative disorders in which protein misfolding leads to brain amyloidosis, as
pathologic TDP-43 forms neuronal and glial inclusions lacking the features of brain amyloid
deposits [62]. Both HDDD kindreds are examples of FTLD-U with GRN mutation which
links them to other FTLD-U with GRN mutation families. However, the HDDD kindreds
appear to have coexisting memory deficits and AD-type pathology and as many as 20% AD
cases have pathology similar to FTLD-U indicating that these coexisting diseases may be
more frequent than previously realized. Also, TDP-43 proteinopathy may be a component of
a growing number of inclusions of different neurodegenerative diseases and further studies
are needed to determine the prevalence of this proteinopathy. Additional clinicopathological
correlations are required to discern the relationship between genotype, neuropathology, and
clinical phenotype more closely.
A rare form of familial FTLD-U is caused by mutations in the VCP gene, while other cases
of FTLD with ALS are linked to chromosome 9p. The majority of inclusions of sporadic and
Liscic et al. Page 6
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

familial FTLD-U with GRN and VCP mutations contain TDP-43 protein, but FTLD-U with
CHMP2B mutation appears to be an exception with ub-ir positive and TDP-43-negative
inclusions. Also, familial cases of ALS with SOD1 mutations have ub-ir, but TDP-43-
negative inclusions. These data indicate that most, but not all, familial cases of FTLD or
ALS are TDP-43 proteinopathies. Thus, FTLD-U and SALS represent two ends of a
spectrum of disorders that are united by a common pathogenic mechanism TDP-43
proteinopathy which is reinforced by recent discoveries of pathogenic mutations in TARDBP
in some FALS. These dramatic new insights into the molecular genetics and neuropathology
of FTLD-U and ALS have led to a revised nosology of FTLD. These advances will
contribute toward an accurate diagnosis, foster clinicopathological studies, and facilitate the
quest for biomarkers and rational therapeutics.
Acknowledgments
We thank the clinical, genetic, pathology, and technical staff of the collaborating centers for making information
and tissue samples available for this study and we thank the families of patients whose generosity made this
research possible. This work was supported by NIH (National Institute on Aging) grants (P01-AG03991, P50-
AG05681, U01-AG16976), Fulbright Grant 68428174 (RML) and CAPES.
References
1. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal
dementia. Journal of Neurology, Neurosurgery and Psychiatry. 1994; 57:416–418.
2. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on
clinical diagnostic criteria. Neurology. 1998; 51:1546–1554. [PubMed: 9855500]
3. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for
frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar
Degeneration. Acta Neuropathologica. 2007; 114:5–22. [PubMed: 17579875]
4. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and
pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal
Dementia and Pick’s Disease. Archives of Neurology. 2001; 58:1803–1809. [PubMed: 11708987]
5. Liscic RM, Storandt M, Cairns NJ, Morris JC. Clinical and psychometric distinction of
frontotemporal and Alzheimer dementias. Archives of Neurology. 2007; 64:535–540. [PubMed:
17420315]
6. Graham A, Davies R, Xuereb J, et al. Pathologically proven frontotemporal dementia presenting
with severe amnesia. Brain. 2005; 128:597–605. [PubMed: 15634737]
7. Neary D, Snowden JS, Mann DM. Classification and description of frontotemporal dementias.
Annals of the New York Academy of Sciences. 2000; 920:46–51. [PubMed: 11193176]
8. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia.
Neurology. 2002; 58:1615–1621. [PubMed: 12058088]
9. Strong MJ, Kesavapany S, Pant HC. The pathobiology of ALS: a proteinopathy? Journal of
Neuropathology and Experimental Neurology. 2005; 64:649–664. [PubMed: 16106213]
10. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic
lateral sclerosis. Journal of the Neurological Sciences. 1994; 124(Suppl):96–107. [PubMed:
7807156]
11. Mitsuyama Y. Presenile dementia with motor neuron disease in Japan: clinicopathological review
of 26 cases. Journal of Neurology, Neurosurgery and Psychiatry. 1984; 47:953–959.
12. Neary D, Snowden JS, Mann DM, Northen B, Goulding PJ, Macdermott N. Frontal lobe dementia
and motor neuron disease. Journal of Neurology, Neurosurgery and Psychiatry. 1990; 53:23–32.
13. Massman PJ, Sims J, Cooke N, Haverkamp LJ, Appel V, Appel SH. Prevalence and correlates of
neuropsychological deficits in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery
and Psychiatry. 1996; 61:450–455.
Liscic et al. Page 7
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

14. Portet F, Cadilhac C, Touchon J, Camu W. Cognitive impairment in motor neuron disease with
bulbar onset. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders. 2001; 2:23–29.
[PubMed: 11465929]
15. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and
frontotemporal dementia. Neurology. 2002; 59:1077–1079. [PubMed: 12370467]
16. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic
lateral sclerosis patients cognitively normal? Neurology. 2003; 60:1094–1097. [PubMed:
12682312]
17. Mackenzie IR, Feldman HH. Ubiquitin immunohistochemistry suggests classic motor neuron
disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron
disease type represent a clinicopathologic spectrum. Journal of Neuropathology and Experimental
Neurology. 2005; 64:730–739. [PubMed: 16106222]
18. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative
inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical
and Biophysical Research Communications. 2006; 351:602–611. [PubMed: 17084815]
19. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar
degeneration and amyotrophic lateral sclerosis. Science. 2006; 314:130–133. [PubMed: 17023659]
20. Caselli RJ, Windebank AJ, Petersen RC, et al. Rapidly progressive aphasic dementia and motor
neuron disease. Annals of Neurology. 1993; 33:200–207. [PubMed: 8257465]
21. Tsuchiya K, Ozawa E, Fukushima J, et al. Rapidly progressive aphasia and motor neuron disease: a
clinical, radiological, and pathological study of an autopsy case with circumscribed lobar atrophy.
Acta Neuropathologica. 2000; 99:81–87. [PubMed: 10651032]
22. Tsuchiya K, Ikeda K, Haga C, et al. Atypical amyotrophic lateral sclerosis with dementia
mimicking frontal Pick’s disease: a report of an autopsy case with a clinical course of 15 years.
Acta Neuropathologica. 2001; 101:625–630. [PubMed: 11515792]
23. Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia.
Neurology. 2003; 61:349–354. [PubMed: 12913196]
24. Josephs KA, Knopman DS, Whitwell JL, et al. Survival in two variants of tau-negative
frontotemporal lobar degeneration: FTLD-U vs FTLD-MND. Neurology. 2005; 65:645–647.
[PubMed: 16116138]
25. Gunnarsson LG, Dahlbom K, Strandman E. Motor neuron disease and dementia reported among 13
members of a single family. Acta Neurologica Scandinavica. 1991; 84:429–433. [PubMed:
1776392]
26. Chow TW, Miller BL, Hayashi VN, Geschwind DH. Inheritance of frontotemporal dementia.
Archives of Neurology. 1999; 56:817–822. [PubMed: 10404983]
27. Bird T, Knopman D, van Swieten J, et al. Epidemiology and genetics of frontotemporal dementia/
Pick’s disease. Annals of Neurology. 2003; 54(Suppl 5):S29–S31. [PubMed: 12833366]
28. Polvikoski TM, Murray A, Harper PS, Neal JW. Familial motor neurone disease with dementia:
phenotypic variation and cerebellar pathology. Journal of Neurology, Neurosurgery and
Psychiatry. 2003; 74:1516–1520.
29. Rosso SM, Donker KL, Baks T, et al. Frontotemporal dementia in The Netherlands: patient
characteristics and prevalence estimates from a population-based study. Brain. 2003; 126:2016–
2022. [PubMed: 12876142]
30. Martinaud O, Laquerriere A, Guyant-Marechal L, et al. Frontotemporal dementia, motor neuron
disease and tauopathy: clinical and neuropathological study in a family. Acta Neuropathologica.
2005; 110:84–92. [PubMed: 15965697]
31. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex
subunit CHMP2B in frontotemporal dementia. Nature Genetics. 2005; 37:806–808. [PubMed:
16041373]
32. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of
bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature
Genetics. 2004; 36:377–381. [PubMed: 15034582]
Liscic et al. Page 8
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

33. Forman MS, Mackenzie IR, Cairns NJ, et al. Novel ubiquitin neuropathology in frontotemporal
dementia with valosin-containing protein gene mutations. Journal of Neuropathology and
Experimental Neurology. 2006; 65:571–581. [PubMed: 16783167]
34. Morita M, Al Chalabi A, Andersen PM, et al. A locus on chromosome 9p confers susceptibility to
ALS and frontotemporal dementia. Neurology. 2006; 66:839–844. [PubMed: 16421333]
35. Vance C, Al Chalabi A, Ruddy D, et al. Familial amyotrophic lateral sclerosis with frontotemporal
dementia is linked to a locus on chromosome 9p13.2–21.3. Brain. 2006; 129:868–876. [PubMed:
16495328]
36. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative
frontotemporal dementia linked to chromosome 17. Nature. 2006; 442:916–919. [PubMed:
16862116]
37. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive
frontotemporal dementia linked to chromosome 17q21. Nature. 2006; 442:920–924. [PubMed:
16862115]
38. Mukherjee O, Pastor P, Cairns NJ, et al. HDDD2 is a familial frontotemporal lobar degeneration
with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal
peptide of progranulin. Annals of Neurology. 2006; 60:314–322. [PubMed: 16983685]
39. Mesulam M, Johnson N, Krefft TA, et al. Progranulin mutations in primary progressive aphasia-
the PPA1 and PPA3 families. Archives of Neurology. 2007; 64:314–322.
40. Behrens MI, Mukherjee O, Tu PH, et al. Neuropathologic heterogeneity in HDDD1: a familial
frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation.
Alzheimer Disease and Associated Disorders. 2007; 21:1–7. [PubMed: 17334266]
41. Benussi L, Binetti G, Sina E, et al. A novel deletion in progranulin gene is associated with
FTDP-17 and CBD. Neurobiology of Aging. 2008; 29:427–435. [PubMed: 17157414]
42. Masselis M, Momeni P, Meschino W, et al. Novel splicing mutation in the progranulin gene
causing familial corticobasal syndrome. Brain. 2006; 129:3115–3123. [PubMed: 17030534]
43. Spina S, Murrell J, Huey E, et al. Corticobasal syndrome associated with the A9D progranulin
mutation. Journal of Neuropathology and Experimental Neurology. 2007; 66:892–900. [PubMed:
17917583]
44. Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-
positive frontotemporal lobar degeneration. Human Molecular Genetics. 2006; 15:2988–3001.
[PubMed: 16950801]
45. Huey ED, Grafman J, Wassermann EM, et al. Characteristics of frontotemporal dementia patients
with a progranulin mutation. Annals of Neurology. 2006; 60:374–380. [PubMed: 16983677]
46. Josephs KA, Ahmed Z, Katsuse O, et al. Neuropathologic features of frontotemporal lobar
degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. Journal
of Neuropathology and Experimental Neurology. 2006; 66:142–151. [PubMed: 17278999]
47. Rademakers R, Baker M, Gass J, et al. Phenotypic variability associated with progranulin
haploinsufficiency in patients with the common 1477C–>T (Arg493X) mutation: an international
initiative. Lancet Neurology. 2007; 6:857–868. [PubMed: 17826340]
48. Spina S, Murrell JR, Huey ED, et al. Clinicopathologic features of frontotemporal dementia with
progranulin sequence variation. Neurology. 2007; 68:820–827. [PubMed: 17202431]
49. Mukherjee O, Wang J, Gitcho M, et al. A Molecular characterization of novel progranulin (GRN)
mutations in frontotemporal dementia. Human Mutation. 2008; 29:512–521. [PubMed: 18183624]
50. Mackenzie IR, Baker M, Pickering-Brown S, et al. The neuropathology of frontotemporal lobar
degeneration caused by mutations in the progranulin gene. Brain. 2006; 129:3081–3090. [PubMed:
17071926]
51. Ikeda M, Ishikawa T, Tanabe H. Epidemiology of frontotemporal lobar degeneration. Dementia
and Geriatric Cognitive Disorders. 2004; 17:265–268. [PubMed: 15178933]
52. Rademakers R, Cruts M, van Broeckhoven C. Epidemiology of frontotemporal dementia and
related tauopathies. Human Mutation. 2004; 24:277–295. [PubMed: 15365985]
53. Josephs KA, Holton JL, Rossor MN, et al. Frontotemporal lobar degeneration and ubiquitin
immunohistochemistry. Neuropathology and Applied Neurobiology. 2004; 30:369–373. [PubMed:
15305982]
Liscic et al. Page 9
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

54. Gitcho MA, Baloh RH, Chakraverty S, et al. TDP-43 A315T mutation in familial motor neuron
disease. Annals of Neurology. 2008; 63:535–538. [PubMed: 18288693]
55. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic
lateral sclerosis. Science. 2008; 319:1668–1672. [PubMed: 18309045]
56. Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and
familial amyotrophic lateral sclerosis. Nature Genetics. 2008; 40:572–574. [PubMed: 18372902]
57. Van Deerlin VM, Leverenz JB, Bekris LM, et al. TARDBP mutations in amyotrophic lateral
sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet
Neurology. 2008; 5:409–416. [PubMed: 18396105]
58. Lipton AM, White CL III, Bigio EH. Frontotemporal lobar degeneration with motor neuron
disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta
Neuropathologica. 2004; 108:379–385. [PubMed: 15351890]
59. Leigh PN, Whitwell H, Garofalo O, et al. Ubiquitin-immunoreactive intraneuronal inclusions in
amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain. 1991; 114:775–
788. [PubMed: 1646064]
60. Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic
lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Annals of Neurology.
2007; 61:427–434. [PubMed: 17469116]
61. Tan CF, Eguchi H, Tagawa A, et al. TDP-43 immunoreactivity in neuronal inclusions in familial
amyotrophic lateral sclerosis with or without SOD1 gene mutations. Acta Neuropathologica. 2007;
113:535–542. [PubMed: 17333220]
62. Cairns NJ, Neumann M, Bigio EH, et al. TDP-43 in familial and sporadic frontotemporal lobar
degeneration with ubiquitin inclusions. American Journal of Pathology. 2007; 171:227–240.
[PubMed: 17591968]
63. Woulfe J, Kertesz A, Munoz DG. Frontotemporal dementia with ubiquitinated cytoplasmic and
intranuclear inclusions. Acta Neuropathologica. 2001; 102:94–102. [PubMed: 11547957]
64. Neumann M, Kwong LK, Truax AC, et al. TDP-43-positive white matter pathology in
frontotemporal lobar degeneration with ubiquitin-positive inclusions. Journal of Neuropathology
and Experimental Neurology. 2007; 66:177–183. [PubMed: 17356379]
65. Neumann M, Kwong LK, Sampathu DM, Trojanowski JQ, Lee VM-Y. TDP-43 proteinopathy in
frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Archives of Neurology. 2007;
64:1388–1394. [PubMed: 17923623]
66. Neumann M, Mackenzie IR, Cairns NJ, et al. TDP-43 in the ubiquitin pathology of frontotemporal
dementia with VCP gene mutations. Journal of Neuropathology and Experimental Neurology.
2007; 66:152–157. [PubMed: 17279000]
67. Sampathu DM, Neumann M, Kwong LK, et al. Pathological heterogeneity of frontotemporal lobar
degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and
novel monoclonal antibodies. American Journal of Pathology. 2006; 169:1343–1352. [PubMed:
17003490]
68. Mackenzie IRA, Rademakers R. The molecular genetics and neuropathology of frontotemporal
lobar degeneration: recent developments. Neurogenetics. 2007; 8:237–248. [PubMed: 17805587]
69. Amador-Ortiz C, Lin W-L, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis
and Alzheimer’s disease. Annals of Neurology. 2007; 61:435–445. [PubMed: 17469117]
70. Nakashima-Yasuda H, Uryu K, Robinson J, et al. Co-morbidity of TDP-43 proteinopathy in Lewy
body related diseases. Acta Neuropathologica (Berlin). 2007; 114:221–230. [PubMed: 17653732]
71. Hasegawa M, Arai T, Akiyama H, et al. TDP-43 is deposited in the Guam parkinsonism-dementia
complex brains. Brain. 2007; 130:1386–1394. [PubMed: 17439983]
72. Holm IE. Ubiquitin-positive inclusions in frontotemporal dementia linked to chromosome 3
(FTD-3). Brain Pathology. 2006; 16(Suppl 1):S43.
73. Davion S, Johnson N, Weintraub S, et al. Clinicopathological correlation in PGRN mutations.
Neurology. 2007; 69:1113–1121. [PubMed: 17522386]
74. Joeng Y, Cho SS, Park JM, et al. 18F-FDG PET findings in frontotemporal dementia: an SPM
analysis of 29 patients. Journal of Nuclear Medicine. 2005; 46:233–239. [PubMed: 15695781]
Liscic et al. Page 10
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

75. Rabinovici GD, Furst AJ, O’Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and
frontotemporal lobar degeneration. Neurology. 2007; 68:1205–1212. [PubMed: 17420404]
76. Whitwell JL, Clifford RJ Jr, Baker M, et al. Voxel-based morphometry in frontotemporal lobar
degeneration with ubiquitin-positive inclusions with and without progranulin mutations. Archives
of Neurology. 2007; 64:371–376. [PubMed: 17353379]
77. Rosen HJ, Allison SC, Schauer GF, et al. Neuroanatomical correlates of behavioral disorders in
dementia. Brain. 2005; 128:2612–2625. [PubMed: 16195246]
78. van der Zee J, Rademakers R, Engelborghs S, et al. A Belgian ancestral haplotype harbours a
highly prevalent mutation for 17q21-linked tau-negative FTLD. Brain. 2006; 129:841–852.
[PubMed: 16495329]
79. Morris JC, Cole M, Banker BQ, Wright D. Hereditary dysphasic dementia and the Pick-Alzheimer
spectrum. Annals of Neurology. 1984; 16:455–466. [PubMed: 6497355]
80. Lendon CL, Lynch T, Norton J, et al. Hereditary dysphasic disinhibition dementia: a
frontotemporal dementia linked to 17q21-22. Neurology. 1998; 50:1546–1555. [PubMed:
9633693]
81. Mackenzie IR, Baker M, West G, et al. A family with tau-negative frontotemporal dementia and
neuronal intranuclear inclusions linked to chromosome 17. Brain. 2006; 129:853–867. [PubMed:
16401619]
82. Snowden JS, Pickering-Brown SM, Mackenzie IR, et al. Progranulin gene mutations associated
with frontotemporal dementia and progressive non-fluent aphasia. Brain. 2006; 129:3091–3102.
[PubMed: 17003069]
83. Strong MJ, Lomen-Hoerth C, Caselli RJ, Bigio EH, Yang W. Cognitive impairment,
frontotemporal dementia, and the motor neuron diseases. Annals of Neurology. 2003; 54(Suppl
5):S20–S23. [PubMed: 12833364]
84. Ludolph AC, Sperfeld AD. Preclinical trials: an update on translational research in ALS. Neuro-
degenerative Diseases. 2005; 2:215–219. [PubMed: 16909028]
85. DiBernardo AB, Cudkowicz ME. Translating preclinical insights into effective human trials in
ALS. Biochimica et Biophysica Acta. 2006; 1762:1139–1149. [PubMed: 16713196]
Liscic et al. Page 11
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Figure 1.
Mutations in the TAR DNA-binding protein 43 (TDP-43) encoded by the TARDBP gene in
familial (FALS) and sporadic amyotrophic lateral sclerosis (SALS). Schematic diagram of
functional domains and mutations in the coding region are indicated using the amino acid
numbering of the 414 amino acid protein. RRM1, RNA recognition motif 1; RRM2, RNA
recognition motif 2; NL, nuclear localization signal; NE, nuclear export signal; hnRNP,
heterogeneous nuclear ribonucleoprotein interaction domain. TARDBP mutations:
autosomal-dominant FALS (black), SALS (green).
Liscic et al. Page 12
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Figure 2.
TDP-43 proteinopathy in FTLD-U. Adjacent sections of superficial frontal neocortex
showing neuronal cytoplasmic inclusions (NCIs), dystrophic neurites (DNs), and isolated
neuronal intranuclear inclusions (NIIs), stained for both ubiquitin (a) and TDP-43 (b). NCIs
in the dentate granule cells stain for ubiquitin (c) and TDP-43 (d). Neuronal and glial
inclusions include: NCI (e), round and lentiform NIIs (f, g); skein-like (h) and compact
round (i) NCIs in lower motor neurons; and a glial cytoplasmic inclusion (GCI) (j). (a, c)
ubiquitin immunohistochemisty; (b, d, e–j) TDP-43 immunohistochemistry. Bars 10 μm (a–
d); 5 μm (e–j). Source: Cairns et al. [60] with permission from the American Society for
Investigative Pathology.
Liscic et al. Page 13
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Figure 3.
FTLD-U subtypes 1–4. (a) Type 1 is characterized by long dystrophic neurites (DNs) in
laminae II/III with relatively few neuronal cytoplasmic inclusions (NCIs) and no neuronal
intranuclear inclusion (NII). (b) Type 2 has numerous NCIs, relatively few DNs, and no NII.
(c) Type 3 has numerous NCIs and DNs and an occasional NII. (d) Type 4 pathology is
characterized by numerous NIIs and DNs but few NCIs. TDP-43 immunohistochemistry.
Bar 10 μm (a–d). Source: Cairns et al. [60] with permission from the American Society for
Investigative Pathology.
Liscic et al. Page 14
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.
NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript
Liscic et al. Page 15
Table 1
Neuropathologic diagnostic criteria for FTLD
1Tauopathy (with associated neuron loss and gliosis) and insoluble tau with a predominance of 3R tau, the most likely diagnoses are:
•FTLD with Pick bodies
•FTLD with MAPT mutation
2Tauopathy (with associated neuron loss and gliosis) and insoluble tau with a predominance of 4R tau, the most likely diagnoses are:
•Corticobasal degeneration
•Progressive supranuclear palsy
•Argyrophilic grain disease
•Sporadic multiple system tauopathy with dementia
•FTLD with MAPT mutation
3Tauopathy (with associated neuron loss and gliosis) and insoluble tau with a predominance of 3R and 4R tau, the most likely
diagnoses are:
•Neurofibrillary tangle dementia
•FTLD with MAPT mutation
4Frontotemporal neuronal loss and gliosis without tau- or ubiquitin/p62- positive inclusions, the most likely diagnoses is:
•FTLD (also known as dementia lacking distinctive histologic features)
5TDP-43 proteinopathy with associated neuronal loss and ubiquitin-positive/p62-positive, tau-negative inclusions, with MND or
without MND but with MND-type inclusions, the most likely diagnoses are:
•FTLD-U with MND (FTLD-U types 1–3)
•FTLD-U but without MND (FTLD-U types 1–3)
•FTLD-U with GRN mutation (FTLD-U type 3)
•FTLD-U with VCP mutation (FTLD-U type 4)
•FTLD-U linked to chromosome 9p (FTLD-U type 2)
•Other as yet unidentified TDP-43 proteinopathies
6Frontotemporal neuronal loss and gliosis with ubiquitin-positive/p62-positive, TDP-43- and tau-negative inclusions, the most likely
diagnoses are:
•FTLD-U with CHMP2B mutation
•Basophilic inclusion body disease (BIBD)
•Other as yet unidentified FTLD-U, non-TDP-43 proteinopathies
7Frontotemporal neuronal loss and gliosis with ubiquitin/p62 and α-internexin-positive inclusions, the most likely diagnosis is:
•Neuronal intermediate filament inclusion disease (NIFID)
CHMP2B, charged multivesicular body protein 2B gene; FTLD, frontotemporal lobar degeneration; FTLD-U, FTLD with ubiquitin-positive, tau-,
α-synuclein-, TDP-43-, and neuronal intermediate filament protein-negative inclusions; MAPT, microtubule-associated protein tau gene; MND,
motor neuron disease; neurofibrillary tangle dementia, also called tangle predominant form of senile dementia; GRN, granulin gene; TDP-43, TAR
DNA-binding protein 43; VCP, valosin-containing protein gene. Reprinted from Ref. [3] with permission of the Editor.
Eur J Neurol. Author manuscript; available in PMC 2010 January 4.